Quest Diagnostics (DGX) continues to draw interest after recent share price swings, with the stock down around 8% over the past month but showing a positive total return over the past 3 months and year.
See our latest analysis for Quest Diagnostics.
The recent 30 day share price return of negative 7.7% contrasts with a 12.5% year to date share price gain and a 1 year total shareholder return of 17.7%. This suggests momentum has cooled after a stronger run, but longer term holders have still seen solid value creation.
If Quest Diagnostics has you thinking about where else growth or resilience might be emerging in healthcare, this is a good moment to scan 34 healthcare AI stocks
With Quest Diagnostics trading around $195.51 and estimates implying both a discount to some price targets and a gap to certain intrinsic value assessments, you have to ask: is there real upside here, or is the market already pricing in future growth?
Most Popular Narrative: 10.5% Undervalued
At a last close of $195.51 against a most-followed fair value estimate of $218.50, the current price sits below what this narrative framework implies, putting the focus firmly on the earnings and cash flow story that underpins that gap.
The analysts have a consensus price target of $218.5 for Quest Diagnostics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $235.0, and the most bearish reporting a price target of just $184.0.
Want to see what sits behind that fair value gap? The narrative leans heavily on steady revenue expansion, firmer margins, and a future earnings multiple that assumes Quest holds its ground in diagnostics. Curious which exact growth path and profitability profile are baked into that $218.50 figure? The full narrative spells out the assumptions line by line.
Result: Fair Value of $218.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if reimbursement cuts under PAMA or rising wage and automation costs squeeze margins more than this upbeat narrative suggests.
Find out about the key risks to this Quest Diagnostics narrative.
Next Steps
If this mix of optimism and concern leaves you undecided, consider acting while sentiment is still balanced and evaluate both perspectives through the 3 key rewards and 1 important warning sign
Ready to broaden your opportunity set?
If Quest Diagnostics has sharpened your focus, do not stop here. The next strong idea could be sitting in plain sight, and you will not want to miss it.
- Target consistency by scanning 64 resilient stocks with low risk scores and see which companies score well on resilience and downside protection.
- Uncover potential value by checking 62 high quality undervalued stocks where solid fundamentals and pricing gaps may line up.
- Strengthen your core holdings with solid balance sheet and fundamentals stocks screener (39 results) focused on companies backed by sturdier financial footing.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com